Literature DB >> 10431991

Superficial thrombophlebitis of the legs: a randomized, controlled, follow-up study.

G Belcaro1, A N Nicolaides, B M Errichi, M R Cesarone, M T De Sanctis, L Incandela, R Venniker.   

Abstract

The aim of the present study was to evaluate the effects of different treatment plans (compression only, early surgery, low-dose subcutaneous heparin [LDSH], low-molecular-weight heparin [LMWH], and oral anticoagulant [OC] treatment) in the management of superficial thrombophlebitis (STP), by considering efficacy and costs in a 6-month, randomized, follow-up trial. Patients with STP, with large varicose veins without any suspected/documented systemic disorder, were included. Criteria for inclusion were as follows: presence of varicose veins; venous incompetence (by duplex); a tender, indurated cord along a superficial vein; and redness and heat in the affected area. All patients were ambulatory. Exclusion criteria were obesity, cardiovascular or neoplastic diseases, bone/joint disease, problems requiring immobilization, and age > 70 years. Patients with superficial thrombophlebitis without varicose veins and patients under treatment with drugs at referral were also excluded. Color duplex (CD) was used to detect concomitant deep vein thrombosis (DVT) and to evaluate the extension or reduction of STP at 3 and 6 months. Venography was not used. Of 562 patients included, 3.5% had had a recent DVT in the same limb affected by SVT and 2.1% in the contralateral limb. In six patients DVT was present in both limbs. These patients were treated with anticoagulants and excluded from the follow-up. After 3 and 6 months the incidence of STP extension was higher in the elastic compression and in the saphenous ligation groups (p < 0.05). There was no significant difference in DVT incidence at 3 months among the treatment groups. Stripping of the affected veins was associated with the lowest incidence of thrombus extension. The cost for compression alone was the lowest and the cost including LMWH was the highest. The average cost was 1,383 US$. However the highest social cost (lost working days, inactivity) was observed in subjects treated only with stockings.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10431991     DOI: 10.1177/000331979905000701

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  13 in total

1.  Superficial thrombophlebitis followed by pulmonary embolism.

Authors:  A Huang; K S Hindle
Journal:  J R Soc Med       Date:  2001-07       Impact factor: 5.344

2.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis.

Authors:  S W Rathbun; C E Aston; T L Whitsett
Journal:  J Thromb Haemost       Date:  2012-05       Impact factor: 5.824

Review 4.  [Superficial venous thrombosis. A review].

Authors:  C Jeanneret; S Brunner
Journal:  Hautarzt       Date:  2012-08       Impact factor: 0.751

5.  Prevalence of Isolated Asymptomatic Deep Vein Thrombosis in Varicose Vein Patients with Superficial Thrombophlebitis: A Single Center Experience in Japan.

Authors:  Nozomu Shirasugi; Sadaaki Horiguchi; Hiroyuki Shirato; Toshimitsu Kawakami; Hisako Ono; Shiho Yabuki; Kumiko Jojima; Masanori Niimi
Journal:  Ann Vasc Dis       Date:  2015-12-31

6.  Physician compliance with outpatient oral anticoagulant guidelines in Auvergne, France.

Authors:  Marc Ruivard; Christine Berger; Abdellaziz Achaibi; Claude Campagne; Pierre Philippe
Journal:  J Gen Intern Med       Date:  2003-11       Impact factor: 5.128

7.  Clinical Features and Developing Risks of Saphenous Vein Thrombophlebitis.

Authors:  Hiroto Rikimaru
Journal:  Ann Vasc Dis       Date:  2016-05-04

Review 8.  Superficial venous thrombosis: disease progression and evolving treatment approaches.

Authors:  Maria E Litzendorf; Bhagwan Satiani
Journal:  Vasc Health Risk Manag       Date:  2011-08-31

9.  Variability in the Management of Superficial Venous Thrombophlebitis across Practitioners Based in North America and the Global Community.

Authors:  Anahita Dua; Jennifer A Heller; Bhavin Patel; Sapan S Desai
Journal:  Thrombosis       Date:  2014-10-12

Review 10.  Treatment for superficial thrombophlebitis of the leg.

Authors:  Marcello Di Nisio; Iris M Wichers; Saskia Middeldorp
Journal:  Cochrane Database Syst Rev       Date:  2018-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.